Literature DB >> 1549377

Prevention and management of office allergy emergencies.

B R Gordon1.   

Abstract

Acute anaphylaxis is a rare, potentially fatal, multisystem allergic reaction that every allergy office must be prepared to treat. Key points are reaction prevention, diagnosing the serious reaction, proper staff training, and keeping on hand (readily accessible and in functioning condition) adequate supplies to provide emergency treatment appropriate to the office locale. The diagnosis of, and treatment for, each common type of allergic reaction is discussed. Equipment and medicines suggested for office use are reviewed, and a sample allergy reaction management protocol is outlined. Office treatment of anaphylaxis is directed at stabilizing the patient for early transport to a hospital. Early administration of epinephrine is the most crucial step. The airway is maintained, circulation supported, and further mediator effects blocked. Cardiopulmonary resuscitation is used whenever respiration or circulation is insufficient. Stabilized patients should be transported as soon as possible by the most medically capable method available, preferably by ambulance with medical personnel in attendance. Because of the risk of subsequent delayed onset or late-phase reactions, and the possibility of multiorgan injury, anaphylaxis patients should be considered for admission to the hospital, extended observation, and appropriate specialist consultations.

Entities:  

Mesh:

Year:  1992        PMID: 1549377

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  3 in total

Review 1.  Dealing with office emergencies. Stepwise approach for family physicians.

Authors:  Ian P Sempowski; Robert J Brison
Journal:  Can Fam Physician       Date:  2002-09       Impact factor: 3.275

Review 2.  Office management of childhood vaccine-related anaphylaxis.

Authors:  J L Thibodeau
Journal:  Can Fam Physician       Date:  1994-09       Impact factor: 3.275

3.  Changes in Peak Flow value during immunotherapy administration.

Authors:  Diego Saporta
Journal:  J Environ Public Health       Date:  2012-02-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.